SCHEMBL13405983

SCHEMBL13405983

COc1cccc(-c2nc3cccc(C)c3[nH]2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIN1 Q13526 1/20 0.53
▸ AURKA O14965 1/20 0.51
▸ NPC1 O15118 3/20 0.50
▸ RAB9A P51151 3/20 0.50
▸ TP53 P04637 2/20 0.50
▸ HPGD P15428 2/20 0.50
▸ POLB P06746 2/20 0.50
▸ NR1I2 O75469 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ VDR P11473 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CYP2B6 P20813 1/20 0.50
▸ AHR P35869 1/20 0.50
▸ NR1I3 Q14994 1/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ PKM P14618 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ KDM4E B2RXH2 2/20 0.49
▸ ALDH1A1 P00352 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14091289 0.80 ADORA2A (0.59) AURKA
SCHEMBL6368201 0.80 NPC1 (0.55) PIN1NPC1RAB9ATP53HPGD
SCHEMBL13406018 0.80 PDE2A (0.52) NPC1RAB9AHPGDPOLBCYP1A2
SCHEMBL29528892 0.79 NPC1 (0.70) AURKANPC1RAB9ATP53HPGD
SCHEMBL830598 0.79 NPC1 (0.70) AURKANPC1RAB9ATP53HPGD
SCHEMBL5201587 0.79 NPC1 (0.47) NPC1RAB9ATP53HPGDPOLB
SCHEMBL31053400 0.79 PARP1 (0.67) PIN1PARP1
SCHEMBL179157 0.77 NPC1 (0.63) PIN1AURKANPC1RAB9ATP53
SCHEMBL20425475 0.76 PIN1 (0.66) PIN1AURKANR1I2CYP1A2VDR
SCHEMBL13406016 0.75 PBRM1 (0.45) NPC1RAB9ATP53HPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705031-B2 Benzimidazoles useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-27 — — US disclosed
US-7705031-B2 Benzimidazoles useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-27 — — US disclosed
US-20080306129-A1 BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2008-12-11 — — US disclosed
US-20080306129-A1 BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2008-12-11 — — US disclosed
US-7309716-B2 Benzimidazoles useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-12-18 — — US disclosed
US-7309716-B2 Benzimidazoles useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-12-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306129-A1 BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS KCNJ11, KCNJ1, KCNJ2 PIN1 3143/4885AURKA 2601/4885NPC1 1008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback